Dr. Ann Cornwall Collier (born 1953)

2021 Videohttps://www.youtube.com/watch?v=Ckq_7BKBsds 2021-01-08-the-amp-aids-memorial-pathway-dr-ann-collier-img-1-collier-portrait.jpg

Wikipedia 🌐 NONE


ASSOCIATIONS

Associate of Dr. Lawrence (Larry) Corey -

From 1997 - Thomas Parran Award Lecture - Award to LAWRENCE COREY - "Raising the Consciousness for Identifying and Controlling Viral STDs: Fears and Frustrations"

PDF : [HE005H][GDrive] / PDF with local OCR : [HE005I][GDrive] / Text version : [HE005JI][GDrive]

"But the malaise was short-lived because HIV arrived. In 1985, Bob Coombs came to Seattle as a postdoctoral fellow to work on HPV. The immunodeficiency syndrome of gay men was being tracked by [Dr. Ann Cornwall Collier (born 1953)] and Hunter Handsfield in Seattle, and it became clear that we needed to initiate a virological program in HIV. Shortly after HIV was identified, Bob went to Martin Hirsch's laboratory at Massachusetts General Hospital to learn how to culture HIV. From 1986 until my sabbatical in 1993 with Ed Mocarski at Stanford, HIV was a constant preoccupation [43-47]. It is still one as we in our group struggle on the difficult issues of how to develop an effective HlV-1 vaccine [48-53].

With [Dr. Ann Cornwall Collier (born 1953)], I established the University of Washington ACTU, one of the original 14. My colleagues graced me with chairing the executive committee of the largest clinical trials program in history. It grew from 14 LO over 53 academic medical center ."


Biographies

2021 (July) bio for "Ann C. Collier, MD" at U.Washington Division on Allergy & Infectious Diseases

https://aid.uw.edu/faculty/ann-c-collier-md

2021-07-univ-washington-aid-uw-edu-faculty-ann-c-collier-md-about-img-1.jpg

https://drive.google.com/file/d/1KP3FBWNZM35gL79wh2SBqN0vXufdF55F/view?usp=sharing

2021-07-univ-washington-aid-uw-edu-faculty-ann-c-collier-md-about.pdf

https://drive.google.com/file/d/1pUhQONURW1Ke6d9F_sFCJ8PwOMAoQm1v/view?usp=sharing

ProfessorDepartment of Medicine, Division of Allergy & Infectious Diseases

Director, UW AIDS Clinical Trials Unit

Associate Director, Center for AIDS Research

Dr. Collier's ongoing clinical research interests include antiretroviral therapy, HIV reservoirs and cure, natural and treated history of primary HIV infection, and the effects of antiretroviral therapy on neurological aspects of HIV infection.

Her ongoing studies include collaborative projects to investigate long-acting antiretroviral drugs and regimens, third line antiretroviral treatment in resource-limited settings, observational studies to evaluate factors associated with HIV reservoir size and long-term outcomes in treated HIV infection, determinants of successful screening for participation in AIDS Clinical Trials Group protocols, and a variety of pilot studies of antiviral and anti-inflammatory agents.

Dr. Collier's ongoing collaborations include local projects with Drs. Joanne Stekler, James Mullins, Christina Marra, Sarah Holte, and Robert Coombs as well as collaborations with other U.S.-based and international colleagues.

Sample projects that trainees might become involved with include third line antiretroviral treatment in resource-limited settings, transition of care from research to clinical care settings, barriers for the conduct of clinical trials in resource-limited settings, determinants of HIV reservoir size, and impact of treatment of acute HIV infection on latently infected CD4 T cells.

Education & Training:

  • MDGeisel School of Medicine at DartmouthHanover, NH1978

  • Intern, Mixed Medicine-Pediatrics ProgramNorth Carolina Memorial HospitalChapel Hill, NC1978-1979

  • ResidentUniversity of WashingtonSeattle, WA 1979-1981

  • Chief Medical Resident, Attending in MedicineDartmouth-Hitchcock Medical CenterHanover, NH/White River Junction, VT1981-1982

  • Fellow in Infectious DiseasesUniversity of WashingtonSeattle, WA 1982-1985

  • Post-Doctoral Research Fellow, Tumor BiologyFred Hutchinson Cancer Research CenterSeattle, WA 1984-1986

Honors:

  • Phi Beta Kappa

  • National Library of Medicine Women Physicians Local Legend

  • American Medical Women's Association Award

  • National Library of Medicine Women Physicians Local Legend

Noted publications:

Maenza J, Tapia K, Holte S, Stekler JD, Stevens CE, Mullins JI, Collier AC. How often does treatment of primary HIV lead to post-treatment control? Antivir Ther. 2015; 20(8):855-63.

• PubMed Abstract

Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, Maenza J, Stevens CE, Buskin SE, Mullins JI, Frenkel LM, Collier AC. Lack of resistance to integrase inhibitors among antiretroviral-naïve subjects with primary HIV-1 infection, 2007-2013. Antiviral Therapy 2015; 20(1):77-80.

• PubMed Abstract

Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. Partner-focused adherence intervention for second-line antiretroviral therapy: A multinational randomized trial (ACTG A5234). Lancet HIV. 2015 Jan 1; 2(1):e12-e19.

• PubMed Abstract

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC and the ACTG 5202 Team. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 2014; 58(4):555-63.

• PubMed Abstract

Zheng L, Taiwo B, Gandhi RT, Hunt PW, Collier AC, Flexner C, Bosch RJ. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. JAIDS. 2014 Oct 1; 67(2):153-60.

• PubMed Abstract

Marra CM, Deutsch R, Collier AC, Morgello S, Letendre S, Clifford D, Gelman B, McArthur J, McCutchan JA, Simpson DM, Duarte NA, Heaton RK and Grant. Neurocognitive impairment in HIV-infected individuals with previous syphilis. Intern J STDs AIDS. 2013 May; 24(5):351-5.

• PubMed Abstract

https://www.uwmedicine.org/bios/ann-collier#about-tab

Accepting new and returning patients

Please call to schedule an appointment with this provider.

Ann C. Collier M.D.

Medical Specialties

AIDS care

Allergy and immunology

Infectious diseases

Internal medicine

OVERVIEW

ABOUT ME

About Ann C. Collier


Anne C. Collier, M.D., is a board certified physician, director of the UW’s AIDS Clinical Trials Unit at Harborview and a UW professor of Allergy and Infectious Diseases and Medicine. She is also associate director of the UW/Fred Hutchinson Cancer Research Center for AIDS Research. She was named a National Library of Medicine Women Physicians Local Legend in 2005.


As a physician, what excites her the most is the opportunity to help patients take advantage of recent advances in medicine and medical care.


Dr. Collier earned her M.D. with honors from Dartmouth. She is a fellow of the Infectious Diseases Society of America and is board certified in Infectious Disease and Internal Medicine. She conducts research about antiretroviral therapy, neurologic aspects of HIV and primary HIV infection. Her current research interests include the locations where HIV hides during effective therapy.

Personal Interests


In her free time Dr. Collier enjoys being a mother, exercise of many types (including in-line skating, swimming, downhill and cross-country skiing, hiking and water aerobics) and gardening.

Education and Training


Geisel School of Medicine at Dartmouth

Medical education, 1978

Univ. of Washington

Fellowship, Infectious Diseases

Univ. of Washington

Residency, Medicine

Univ. of North Carolina Hospitals

Internship, Internal Medicine/Pediatrics

Geisel School of Medicine at Dartmouth

Residency, Medicine

Board Certifications


Infectious Disease, 1984, American Board of Internal Medicine

Internal Medicine, 1981, American Board of Internal Medicine


https://www.youtube.com/watch?v=9Fjkzhu0d9U

DR. ANN COLLIER EXPLAINS WHY THE ACTG NETWORK IS CONDUCTING COVID-19 RESEARCH

32 viewsJun 6, 2020

Michael W

The introduction from our April 28, 2020 Community Advisory Board meeting, where our Director, Dr. Ann Collier gives some background on COVID-19 and explains what led the AIDS Clinical Trials Group, a federally funded HIV treatment research network, to conduct COVID-19 research.

2020-06-06-youtube-michael-w-ann-collier-explains-why-the-actg-network-is-conducting-covid19-research-720p.mp4

2020-06-06-youtube-michael-w-ann-collier-explains-why-the-actg-network-is-conducting-covid19-research-img-1.jpg



https://www.youtube.com/watch?v=Ckq_7BKBsds

Dr. Ann Collier

62 viewsJan 8, 2021

The AMP: AIDS Memorial Pathway

Dr. Ann Collier, a UW infectious disease researcher and physician, who helped create HIV care via HMC, talks about stigma, global HIV treatment, and the naming of Madison Clinic, as well as the first cases of HIV cure.

2021-01-08-the-amp-aids-memorial-pathway-dr-ann-collier.mp4

2021-01-08-the-amp-aids-memorial-pathway-dr-ann-collier-img-1-collier-portrait.jpg


ALso see :

https://www.youtube.com/watch?v=NibceBv7g_Q

ALLRT Study Leads to Breakthroughs in HIV Research

126 viewsDec 5, 2013

ACTGNetwork

=

Our Drs. Ann Collier and Constance Benson discuss the advances made in HIV research thanks to the AIDS Clinical Trials Group (ACTG) Network's A5001 ALLRT study. The study began in 2000 as follow-up study for people living with HIV in the United States who were already enrolled in a parent ACTG study.


Directory Info

https://www.ancestry.com/discoveryui-content/view/271672111:62209?tid=&pid=&queryId=df4c345c9b1f9d00ffbdbebd7146887e&_phsrc=llt534&_phstart=successSourceAnn Cornwall Collier[A Vandergrift Lindsey][A C Dr Collier][Ann Cornwall Collier][Ann Cornwall Vandergrift]Birth Date: Nov 1953Residence Date: 1988-2020Address: 11411 Arroyo Beach Pl SWResidence: Seattle, Washington, USAPostal Code: 98146Second Residence Date: 2003-2017Second Address: 325 9th AveSecond Residence: Seattle, Washington, USASecond Postal Code: 98104Third Residence Date: 2008-2011Third Address: Po Box 50095Third Residence: Seattle, Washington, USAThird Postal Code: 98145


Evidence Timeline


1983 (April 22)

3A - https://www.newspapers.com/image/182477690/?terms=%22Dr.%20Ann%20Collier%22&match=1

1983-04-22-courier-post-camden-nj-pg-3a

4A- https://www.newspapers.com/image/182477813

1983-04-22-courier-post-camden-nj-pg-4a

1983-04-22-courier-post-camden-nj-pg-3a-clip-illness.jpg

1983 (Aug 22)

https://www.newspapers.com/image/576617511/?terms=%22Dr.%20Ann%20Collier%22&match=1

1983-08-22-longview-daily-news-longview-washington-pg-6

1983-08-22-longview-daily-news-longview-washington-pg-6-clip-aids-death

1990 (October) - Outweek Magazine : "AIDS THIS WEEK: Studies Confirm Low-Dose AZT Benefit"

Edited by Paul Rykoff Coleman / PDF = [HP007M][GDrive]

NEW YORK- AZT: It works best at low doses. It's toxic at any dose. It'll prolong your life. It'll kill you. No matter what people say about it, AZT is still the only drug approved" for treating the human immunodeficiency virus.

Two studies published recently show that AZT taken in doses much lower than the original standard dose - 900 mg less per day - are just as effective with fewer adverse effects. These are not the first studies to suggest low-dosing with AZT, and AIDS physicians, especially those in urban areas, have been prescribing low doses for some time.

Nevertheless, those with qualms about the drug say that they're concerned about adverse effects that appear over time. Even so, both supporters and critics are looking toward combination therapy, in which two or three drugs taken together at low doses will attack HIV synergistically. Those critics charge that better therapies will be available only if the National Institute of Allergy and Infectious Diseases stops its obsession with testing AZT virtually exclusively and moves on to other agents.

"AZT is a political issue,' said Steve Machon, president of the board of AIDS Treatment Registry, an educational advocacy organization dealing with clinical trials for people with AIDS. "It appears that the longest-term survivors are people who've used AZT for a limited amount of time or not at all."

The drug's manufacturer, Burroughs Wellcome Co., and NIAlD say otherwise.

Kathy Bartlett, a Wellcome spokesperson, estimated that "tens of thousands' of people with HIV infection were taking AZT and were surviving longer because of it. And at NWD, an official said that she was perplexed why the articles, by Dr. Margaret Fischl at the University of Miami and [Dr. Ann Cornwall Collier (born 1953)] at the University of Washington, received attention in the mainstream press. "We were a little surprised when there were stories about them," said [Deborah Phyllis (Grossman) Katz (born 1948)] special assistant to Dan Hoth, who heads the AIDS division at NIAlD. 'They're old news. It was just information that finally appeared in the medical literature."

Not according to Collier: "Dr. Fischl's study has had a major impact and should not be underestimated just because it has already happened,' she said.

Indeed, Fischl's study was used by Wellcome to get the US Food and Drug Administration last January to officially lower the dose from 1500 mg per day to 600 mg per day for people with AIDS. Collier's study compared effectiveness of three daily doses, 300 mg, 600 mg and 1500 mg, in those with AIDS-related complex, a stage of HIV infection in which symptoms appear but the HIV infection has not progressed to AIDS as defined by the US Centers for Disease Control. Both were published in the Oct. 11 issue of the New England Journal of Medicine.

600mg?

Fischl, working with a number of

researchers across the country and the

NIAID's AIDS Clinical Trials Group,

concluded that 600 mg per day was as

effective as, and iess toxic than, 500 mg.

Those in her study had to have had

a previous bout of Pneumocystis carinii

pneumonia. The study was randomized,

meaning that none of the 524 subjects

could choose their dose-either 250 mg

for lesbians and gay men.

In a letter dated Oct. 15, the Supervisors

warned GM that "as part of

GM's financial relationship with the ,

city, your corporation agrees not to

engage in discriminatory practices

against lesbians and gay men. Natu-

. rally, we are outraged that GM's

. Chevrolet division has chosen to violate

its agreement with San Francisco

and to, subfect lesbian and gay people

to the hqrrors of prejudice and

injustice:" A spokesperson from

Chevrolet did not return a reporter's

phone call. On Oct. 16, a spokesperson

told the San Francisco Examimer,

"We sincerely apologize to anyone

who was offended and will take every

precaution to ensure that nothing like

this ever happens again."

"This video didn't just happen,"

remarked TJ Anthony, an openly gay

aide to Supervisor Hongisto, pointing

out that the interView was culled from

more than 500 hours of tape, reviewed

by the promotional division of Chevrolet,

and released as part of a coordinated

effort to 'up sales. "That means

there was a consensus of bigotry

among the GM promotional people,"

Anthony concluded.

Currently, according to Anthony,

the city is awaiting a response from

GM to a letter signed by all of the city

supervisors, and a report on GM from

the Human Rights Commission. Anthony

said that part of his negotiations

with GM include a request that the international

corporation donate a sum

equal to the amount of money spent

on the video to a gay and lesbian community-

based organization that fights

violence and discrimination.

An editorial in the San Francisco

Examiner urged citizens to go even farther

in their actions against the company:

"Boycott [GM's]big, macho trucks.

Japanese trucks work better anyway,

and you don't have to wipe the slime off

the door handles," the piece suggested.





2020 (Nov 05)

https://www.nejm.org/doi/full/10.1056/NEJMp2022269


https://www.geekwire.com/2020/uw-medicine-ramps-study-hydroxychloroquine-azithromycin-covid-19-treatment/


Perspective

Covid-19, Ebola, and HIV — Leveraging Lessons to Maximize Impact

List of authors.

  • Connie Celum, M.D., M.P.H.,

  • Ruanne Barnabas, D.Phil., M.B., Ch.B.,

  • Myron S. Cohen, M.D.,

  • Ann Collier, M.D.,

  • Wafaa El-Sadr, M.D., M.P.H.,

  • King K. Holmes, M.D., Ph.D.,

  • Christine Johnston, M.D., M.P.H.,

  • and Peter Piot, M.D., Ph.D.


2019 (May)

https://pubmed.ncbi.nlm.nih.gov/30990052/


AIDS Res Hum Retroviruses


. 2019 Jul;35(7):649-659. doi: 10.1089/AID.2019.0021.Epub 2019 May 21.

Acceptability of Cell and Gene Therapy for Curing HIV Infection Among People Living with HIV in the Northwestern United States: A Qualitative Study

Karine Dubé 1, Jane Simoni 2 3, Michael Louella 4 5 6, Laurie Sylla 4 6, Zahra H Mohamed 2, Hursch Patel 1, Stuart Luter 1, Ann C Collier 6

Affiliations expand

Free PMC article


Funny !!

2020 (May 15)

https://sciencenewsnet.in/larger-study-to-test-combination-treatment-for-covid-19/

Larger study to test combination treatment for COVID-19

May 15, 2020 sarah JonasVideo Only

Post Views: 289

Researchers are pulling out all the stops to find treatments and cures for patients exposed to COVID-19. And now a larger study at UW Medicine is enrolling participants to determine whether a treatment combining a low dose of hydroxychloroquine and azithromycin can prevent hospitalization and death in people with COVID-19.

Dr. Ann Collier, professor of medicine in the Division of Allergy and Infectious Diseases at the Univerisity of Washington School of Medicine, is the local PI for a study funded by the National Institutes of Health looking to enroll 2,000 outpatients at sites across the country who have tested positive for COVID-19.

This study is separate from a smaller treatment trial at UW Medicine enrolling 630 patients exposed to COVID-19 using the same regimen. Researchers say the two studies are complimentary. In normal times, researchers said one study would be launched before a larger study. But because of the time-sensitive need for answers, a larger study is being launched simultaneously. The smaller study will provide more insight into the virology of the virus. And the larger trial will provide definitive clinical outcomes data.

To enroll, call or text 206-773-7129 or email actu@uw.edu.

Hydroxychloroquine has received considerable hype as a potential treatment for COVID-19 and has been confused with chloroquine, a drug stopped in a treatment trial in Brazil. There is conflicting evidence on whether it works, which is why stronger evidence is needed. The hydroxychloroquine dose used in these studies has been used safely by many people for decades to prevent malaria and other sicknesses.

Multiple studies in different populations are taking place at UW Medicine to answer the critical question on the effectiveness of hydroxychloroquine.


March 2020 - on the Fauci emails

From: Fauci, Anthony (NIH/NIAID) [E)

Sent: Mon, 23 Mar 2020 19:06:06 +0000

Bee: Aberg, Judith;Adaora Adimora;Grund, Birgit;Glidden, David;Daar, Eric;Erica

Hardy;Gandhi, Rajesh Tim,M.D.;Jason Baker;Jeff Lennox;Johnson, Steven C- ID;Kim, Arthur

Y.,M.D.;Marla Keller;Tebas, Pablo (NIH);Susan Davis;Susan Swindells;Susanna Naggie;Tien, Phyllis;Amy

Dzierba;Mitchell Levy;Laura Evans;Craig Coopersmith ;Greg Martin;Uyek i, Timothy M.

(CDC/0010/NCIRD/ ID);Walker, Robert (OS/ASPR/BARDA);Sheikh, Virginia (FDA/CDER);Anne

Collie r;Francis, Joe (Contact NLM/OD -External) (b)(6)

Subject: Invitation to join the HHS Panel on Guidelines for The Management of COVID-19

TUPDB0103

Long-term bone mineral density changes in

antiretroviral-treated HIV-infected individuals

P. Grant1, D. Kitch2, G. McComsey3, A. Collier4, S. Koletar5, K. Erlandson6, M. Yin7, B. Bartali8,

B. Ha9, K. Melbourne10, T. Brown11

1Stanford University, Infectious Diseases, Stanford, United States, 2Harvard School of Public

Health, Boston, United States, 3Case Western Reserve University, Cleveland, United States,

4University of Washington, Seattle, United States, 5Ohio State University, Colombus, United

States, 6University of Colorado, Denver, United States, 7Columbia University, New York,

United States, 8New England Research Institute, Watertown, United States, 9Viiv, Research

Triangle Park, United States, 10Gilead Sciences, Foster City, United States, 11Johns Hopkins

University, Baltimore, United States

Presenting author email: pmgrant72@gmail.com

Background: Accelerated bone mineral density (BMD) loss occurs during the first two

years of ART. Few studies have evaluated subsequent BMD changes, especially compared

to uninfected controls.

Methods: ACTG A5318 performed one follow-up site-specific dual-energy x-ray absorptiometry

(DXA) in HIV-infected individuals who had received baseline and follow-up DXAs during

the randomized treatment trial A5202/A5224s. As controls, we obtained DXA results from uninfected

participants enrolled in BACH/Bone and WIHS cohorts. Repeated measures analyses

compared BMD change rate between HIV-infected and uninfected, adjusting for age, sex, race,

and body mass index (BMI). In the HIV-infected group, we performed multivariable analyses

evaluating association of HIV-specific (baseline and time-updated CD4 and viral load), HIV

treatment-related (randomized ART regimen, cumulative tenofovir [TDF] exposure) and non-

HIV related factors (age, sex, race, relevant concomitant medication use, BMI, total lean body

mass) on BMD change rate.

Results: Baseline characteristics between HIV infected (n=97) and HIV-uninfected (n=630)

participants were generally similar: median age, 40 vs. 46; % female, 14 vs. 14; % black, 34 vs.

35; median BMI, 24 vs. 29; and median years between first and last DXA, 7.5 vs. 6.9. Seventyone

percent of HIV-infected participants were on TDF at last DXA. Compared to controls, HIVinfected

individuals had significantly greater adjusted BMD decline rate at lumbar spine (LS)

and total hip (TH) during the first 96 weeks of ART (both p<0.001). Subsequently, on follow-up

DXA, HIV infection remained significantly associated with greater adjusted BMD decline rate at

LS (-0.29%/year; 95% CI: -0.49, -0.09; p=0.005) but not at TH (p=0.63). In the HIV group, the

rate of BMD decline slowed after the first 96 weeks of ART (0-96 weeks vs. Late Change: LS:

-0.75%/year vs. -0.19%/year, p=0.04; TH: -1.29%/year vs. -0.30%/year, p<0.001). During the

late period, no HIV-related characteristic was associated with BMD loss, but lower total lean

body mass (and not BMI) was associated with greater BMD loss at LS and TH (both p<0.001).

Conclusions: Although the rate of BMD decline slowed after the first 96 weeks after ART

initiation in HIV-infected persons, the rate of bone loss at the lumbar spine was still significantly

greater than HIV-uninfected controls.